Best Chemotherapy hematologist-oncologists in Spain: TOP 8 doctors

• Specializes in chemotherapy for breast cancer using targeted drug therapies.
• Trained in Medical Oncology in Spain and obtained certification in London.
• Member of Spanish Medical Oncology Society and European Society for Medical Oncology.
• Founding Vice President of the Spanish Breast Cancer Research Group.
• Authored over 130 articles focused on oncology and chemotherapy.

• Specializes in intraperitoneal chemotherapy for peritoneal carcinomatosis.
• Trained in the USA, Spain, and Croatia.
• Certified by the American Board of Surgery.
• Member of the American College of Surgeons and Society of Surgical Oncology.
• Performed over 1300 surgeries, including chemotherapy procedures.

Children's Hematologist. Specialist in bone marrow transplantation

Dr. Jaume Mora Graupera is a pediatric oncologist specializing in the treatment of neuroblastomas, gliomas, Ewing's sarcomas, and Wilms' tumors. He is the Director of the Hematology Oncology Department and Developmental Tumors Laboratory at Sant Joan De Déu - Barcelona Children’s Hospital. He received his medical degree from the University of Barcelona, went on to complete specialty training in pediatrics and fellowships in pediatric hematology oncology and molecular pathology of pediatric cancer at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in the USA. He has won multiple awards and is a member of various medical organizations.

• Specializes in managing neurotoxicities from chemotherapy for brain cancers.
• Trained in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center, USA.
• Founder and past president of the European Association of Neuro-Oncology.
• Holds a PhD from Universitat Autónoma de Barcelona.
• Emeritus investigator of IDIBAPS, focusing on neuro-oncological disorders.

This doctor has experience in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy. They have also been involved in numerous phase 1, 2 and 3 studies in breast and melanoma, which have led to the approval of new drugs in new indications. Their main area of interest lies in immunotherapy for melanoma treatment and patient care. They have participated in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, and Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab. They are a member of the Breast Cancer Unit and Melanoma Unit at the Vall d'Hebron University Hospital and the Vall d'Hebron Institute of Oncology. This doctor is an experienced oncologist with expertise in breast cancer and melanoma treatments, including endocrine therapy, immunotherapy, and patient care. They have been involved in numerous clinical trials leading to the approval of new drugs in new indications.